A study finds the rise in U.S. obesity rates have hit a plateau in children but are still climbing for adults, and are still ...

Trial shows patients switching from jabs to oral medication maintain up to 80pc of their weight loss long-term ...

By Stine Jacobsen and Maggie Fick COPENHAGEN/LONDON, May 6 (Reuters) - Novo Nordisk beat first-quarter profit forecasts and ...

Real world data showed clinically meaningful BMI reductions with setmelanotide in 62 adults with 12-month data living with ...

Why rare diseases like hantavirus generate fear while heart disease, loneliness, obesity, and poor sleep quietly cause far ...

European Commission grants authorization in adults and children 4 years of age and above with acquired hypothalamic obesity due to hypothalamic injury or impairment -- BOSTON, May 01, 2026 (GLOBE ...

Novo Nordisk shares surged after strong demand for its new weight-loss pill helped the Danish drugmaker beat quarterly profit ...

Breakthrough research is set to provide relief for huge numbers of people dealing with sleep apnoea – and their long ...

A new study found a decline in the number of people getting bariatric surgery for weight loss due to widespread use of GLP-1 ...

IMCIVREE® (setmelanotide) launched in the U.S. for acquired hypothalamic obesity; more than 150 patient start forms received in the first six weeks following FDA approval on March 19, 2026 -- -- First ...

This continuing education course details the role of GLP-1 injectables in managing chronic conditions and overweight/obesity, ...

Ozempic is now available in pill form for people with type 2 diabetes. Novo Nordisk says the oral GLP-1's new lower-dose ...